These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23057544)

  • 41. Availability of pharmacogenetic and pharmacogenomic information in anticancer drug monographs in France: personalized cancer therapy.
    Albertini L; Siest G; Jeannesson E; Visvikis-Siest S
    Pharmacogenomics; 2011 May; 12(5):681-91. PubMed ID: 21619430
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities.
    Arai RJ; Guindalini RSC; Llera AS; O'Connor JM; Muller B; Lema M; Freitas HC; Soria T; Delgado L; Landaverde D; Montenegro P; Riechelmann RP
    Oncologist; 2019 Aug; 24(8):e709-e719. PubMed ID: 30910864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.
    de Denus S; Dubé MP; Tardif JC
    Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cancer pharmacogenomics: implications on ethnic diversity and drug response.
    Patel JN
    Pharmacogenet Genomics; 2015 May; 25(5):223-30. PubMed ID: 25751395
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics.
    Becquemont L; Alfirevic A; Amstutz U; Brauch H; Jacqz-Aigrain E; Laurent-Puig P; Molina MA; Niemi M; Schwab M; Somogyi AA; Thervet E; Maitland-van der Zee AH; van Kuilenburg AB; van Schaik RH; Verstuyft C; Wadelius M; Daly AK
    Pharmacogenomics; 2011 Jan; 12(1):113-24. PubMed ID: 21174626
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Integrating pharmacogenomics into pharmacy practice via medication therapy management.
    Reiss SM;
    J Am Pharm Assoc (2003); 2011; 51(6):e64-74. PubMed ID: 22001957
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacogenomics: Principles and Relevance to Oncology Nursing
.
    Dodson CH
    Clin J Oncol Nurs; 2017 Dec; 21(6):739-745. PubMed ID: 29149126
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
    La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pharmacogenomics of osteosarcoma.
    Serra M; Hattinger CM
    Pharmacogenomics J; 2017 Jan; 17(1):11-20. PubMed ID: 27241064
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lack Of Diversity In Genomic Databases Is A Barrier To Translating Precision Medicine Research Into Practice.
    Landry LG; Ali N; Williams DR; Rehm HL; Bonham VL
    Health Aff (Millwood); 2018 May; 37(5):780-785. PubMed ID: 29733732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cambridge Healthtech Institute's 2nd Annual Conference on Pharmacogenomics Europe: presaging profits.
    Kerb R; Brinkmann U
    Pharmacogenomics; 2001 Aug; 2(3):303-5. PubMed ID: 11939136
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Pharmacogenomic data for personalized medicines].
    Yamazaki H
    Gan To Kagaku Ryoho; 2005 Nov; 32(12):1886-90. PubMed ID: 16282721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of hospital pharmacists in the adoption and use of pharmacogenomics and precision medicine.
    Schwartz EJ; Issa AM
    Per Med; 2017 Jan; 14(1):27-35. PubMed ID: 29749827
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mass Spectrometry in Precision Medicine: Phenotypic Measurements Alongside Pharmacogenomics.
    Clarke NJ
    Clin Chem; 2016 Jan; 62(1):70-6. PubMed ID: 26555454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
    Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
    Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacogenomics instruction in US and Canadian medical schools: implications for personalized medicine.
    Green JS; O'Brien TJ; Chiappinelli VA; Harralson AF
    Pharmacogenomics; 2010 Sep; 11(9):1331-40. PubMed ID: 20860470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Precision medicine: The future in diabetes care?
    Scheen AJ
    Diabetes Res Clin Pract; 2016 Jul; 117():12-21. PubMed ID: 27329017
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenomic biomarkers for personalized cancer treatment.
    Rodríguez-Antona C; Taron M
    J Intern Med; 2015 Feb; 277(2):201-217. PubMed ID: 25338550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Role of Clinical Pharmacology in Oncology Dose Selection: Advances and Opportunities in Personalized Medicine.
    Shord SS
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S99-S104. PubMed ID: 28921640
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison and validation of genomic predictors for anticancer drug sensitivity.
    Papillon-Cavanagh S; De Jay N; Hachem N; Olsen C; Bontempi G; Aerts HJ; Quackenbush J; Haibe-Kains B
    J Am Med Inform Assoc; 2013; 20(4):597-602. PubMed ID: 23355484
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.